Wave Life Sciences to feature Arun J. Sanyal on RNA editing at Research Day
1 report, 1 independent
Updated Oct 19
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Wave Life Sciences announced it will host a virtual Research Day on November 4, 2026. During the event, the company will share new data highlighting its RNA medicines platform. The event will feature Arun J. Sanyal, a leading hepatologist, providing perspective on an RNA editing correction approach for PNPLA3 I148M liver disease.
From manilatimes.net
Why it matters
The Research Day will showcase Wave Life Sciences' differentiated RNA medicines platform, which includes RNAi, RNA editing, and bifunctional modalities. The participation of Arun J. Sanyal provides expert insight into the company's therapeutic approach for liver disease.
From manilatimes.net
Who's involved
- Arun J. SanyalProvided expert perspective on RNA editing approaches relevant to liver disease.
- Wave Life SciencesBiotechnology company hosting the Research Day and presenting platform data.
- Virginia Commonwealth UniversityAffiliation of Arun J. Sanyal, where he is a professor of medicine.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Wave Life Sciences' RNA editing progress may shift Mizuho's viewWave Life Sciences' scientific progress may influence Mizuho's financial assessment.Possible
- Wave Life Sciences' RNA editing data may strengthen Truist Financial's viewWave Life Sciences' RNA editing data may strengthen Truist Financial's investment viewPossible
- Wave Life Sciences' RNA editing focus may challenge Regeneron PharmaceuticalsWave Life Sciences' focus on RNA editing may increase competition in liver disease treatment.Possible
Keep exploring
The entities involved
-
Arun J. Sanyal
researcher
Nothing else this week.
-
Wave Life Sciences
biotechnology company
Nothing else this week.